Movement disorders News and Research

RSS

ENS, SSIF announce prestigious award to recognize excellence in medical education

Serono Symposia International Foundation (SSIF) has announced today a public competition for an Award to recognise an expert in the field of neurology who has made a significant contribution to medical education activities through research and dedication.

30 May 2011

Omeros' PDE7 program expands addiction franchise

Omeros Corporation today announced that its phosphodiesterase 7 inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

6 May 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Study: DBS surgery allows 77% of patients to stop anti-tremor medication use

Deep brain stimulation, a surgical procedure to suppress faulty nerve signals, allowed 77 percent of patients to stop the medications used to treat their essential tremors within one year following the surgery, University of South Florida researchers report.

8 Apr 2011

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

Patients with dystonia can benefit from deep brain stimulation therapy

Patients suffering from dystonia, an uncommon yet potentially crippling movement disorder, get better results if they begin deep brain stimulation therapy sooner rather than later, according to an international study published in the March issue of the Journal of Neurology.

30 Mar 2011

Cleveland Medical Devices Inc. spins off Great Lakes NeuroTech

Cleveland Medical Devices Inc. (CMDI) has announced the formation of Great Lakes NeuroTech (www.GLNeuroTech.com), a spin-off company which has acquired the rights to develop, market, and manufacture clinical motor assessment and therapy systems for the movement disorders market as well as physiological monitors for research and education markets. Great Lakes NeuroTech (GLN) will perform R&D, engineering, manufacturing, distribution, and exporting of these technologies through two divisions: Movement Disorders and Research & Education Systems.

28 Mar 2011

University of Aberdeen, TPP enter agreement to develop novel future medicines

TPP Global Development Ltd has announced an agreement with the University of Aberdeen to collaborate on the development of novel pre-clinical intellectual property originated within the University.

28 Mar 2011

New discovery may improve cochlear implants for deafness

University of Utah scientists used invisible infrared light to make rat heart cells contract and toadfish inner-ear cells send signals to the brain.

28 Mar 2011

65-year-old woman receives new neurostimulator implant for deep brain stimulation therapy

A 65-year-old woman with Parkinson's disease became the first patient in the United States to receive a new device for deep brain stimulation (DBS) therapy.

17 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Medtronic introduces Activa SC deep brain stimulation system in the U.S. and Europe

With the first U.S. implant of its new Activa SC neurostimulator for deep brain stimulation therapy, Medtronic, Inc. today announced the technology's commercial availability throughout the United States and Europe.

17 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011

St. Joseph's Hospital launches new neuromodulation center in Barrow

St. Joseph's Hospital and Medical Center's Barrow Neurological Institute has received a $10.1 million donation, the largest single gift in the organization's history and one of the biggest ever given to any Arizona hospital.

10 Mar 2011

Researcher launches new DBS clinical trial to pinpoint brain activity in depressed people

A top medical researcher at Barrow Neurological Institute at St. Joseph's Hospital in Phoenix, Arizona, has launched a clinical trial to pinpoint brain activity in depressed people by using scientifically designed sad and heartrending photos and music.

10 Mar 2011

First recording of cortically induced neural activity of basal ganglia in Parkinson's disease, dystonia during DBS

Movement disorders such as Parkinson's diseases and dystonia are caused by abnormal neural activity of the basal ganglia located deep in the brain. The basal ganglia are connected to the cerebral cortex in the brain surface through complex neural circuits.

10 Mar 2011

Noninvasive MR-guided focused ultrasound successfully treats essential tremor

A new chapter in medical history opened days ago when noninvasive MR-guided focused ultrasound was used to successfully treat a patient with essential tremor (ET), a progressive neurological disorder that affects millions of people worldwide and causes involuntary shaking of the hands, head, face, eyelids, voice or other muscles.

10 Mar 2011

Unique gene therapy to combat Parkinson's disease

Physicians at Rush University Medical Center are testing a unique gene therapy product called CERE-120 to evaluate if its use can improve the symptoms of Parkinson's disease. Rush is one of 11 sites in the U.S. and the only site in Illinois enrolling patients into the new, double-blinded trial.

9 Mar 2011